Purpose of review Skeletal muscle loss or sarcopenia is a frequent complication of cirrhosis that adversely affects clinical outcomes. As skeletal muscle is the largest store of proteins in the body, proteostasis or protein homeostasis is required for maintenance of muscle mass. This review will focus on disordered skeletal muscle proteostasis in liver disease.
INTRODUCTION
There is an extensive body of literature, which states that loss of skeletal muscle mass or sarcopenia is a major and common complication in cirrhosis and results in decreased survival, lower quality of life, higher frequency of complications of cirrhosis, and worse postliver transplant outcomes [1 . Even though the term sarcopenia (sarcos: flesh; penia: loss) is literally translated as loss of muscle mass, the term has been used in the aging literature to refer to not only loss of muscle mass, but also skeletal muscle function. Secondary sarcopenia has been suggested to refer to muscle loss in chronic diseases but most publications continue to use the term 'sarcopenia' to refer to loss of skeletal muscle mass even though some use the term to refer to impaired muscle strength also. In this review, the term 'sarcopenia' will refer to loss of skeletal muscle mass unless specifically stated to include impaired contractile function. The clinical importance of sarcopenia is increasingly recognized in the era of liver transplantation because of a variety of reasons that include the relatively low proportion of patients with liver disease who undergo liver transplantation, lack of recovery of muscle mass after transplantation and higher postliver transplantation ,7,10]. Despite the high significance, there are no effective therapies to date, primarily because of limited understanding of the mechanisms that have resulted in an approach of deficiency replacement rather than targeted therapies. Most studies to date have used the principle of overcoming the anabolic resistance, a state in which physiological stimuli including nutrients and physical activity do not result in the expected improvement in skeletal muscle mass or anabolism [11] . As skeletal muscle is the largest protein store in the body, the balance between protein synthesis and proteolysis, components of protein homeostasis (proteostasis) is a major contributor to maintenance of muscle mass [12 && ]. Protein homeostasis is controlled by the coordinated actions of several cellular processes, including protein synthesis and degradation. Studies in cirrhotic patients in the past based on whole body protein turnover studies or arteriovenous differences have reported conflicting results with increased, decreased or unaltered protein synthesis or breakdown. Clarity ensued once data from skeletal muscle biopsies from individuals complemented by studies in rodent and cellular models of sarcopenia of liver disease were published in the past two decades [1
]. In addition to better understanding of skeletal muscle proteostasis, the underlying molecular and metabolic perturbations also have allowed identification of novel, molecular, and metabolic therapeutic targets. The present review will focus on recent advances in muscle proteostasis perturbations, potential mediators of the liver-muscle axis, and the therapeutic possibilities that can help overcome the anabolic resistance of cirrhosis. . These data provide compelling evidence that both arms of proteostasis, protein synthesis, and proteolysis were perturbed with resultant sarcopenia in liver disease.
SKELETAL MUSCLE PROTEOSTASIS IN CIRRHOSIS

SIGNALING DISTURBANCES THAT RESULT IN PERTURBED PROTEOSTASIS
Skeletal muscle protein synthesis is regulated by at least two critical factors: myostatin, a TGFb superfamily member, and locally generated insulin-like growth factor (IGF1), also called mechanogrowth factor [18] . Myostatin results in muscle loss, primarily, by signaling responses that impair the mammalian target of
KEY POINTS
Hyperammonemia is a consistent abnormality in cirrhosis and results in decreased muscle protein synthesis and increased autophagy with resultant loss of muscle mass or sarcopenia.
Myostatin, a TGFb superfamily member is transcriptionally upregulated during hyperammonemia and impairs protein synthesis and may increase proteolysis.
A novel cellular stress response mediated via the GCN2-eIF2a phosphorylation axis with decreased protein synthesis may crosstalk with impaired mTORC1 signaling.
Mitochondrial dysfunction because of cataplerosis of aKG with decreased ATP generation and increased reactive oxygen species is an additional abnormality that contributes to both decreased protein synthesis and increased autophagy.
Lowering ammonia and providing a large dose of leucine to satisfy the metabolic demand may restore proteostasis during hyperammonemia.
Novel therapeutic approaches include myostatin antagonists, anaplerotic substrates and inhibitors of the negative effects of eIF2a phosphorylation on protein synthesis. 0 -m 7 G cap-structure to a protein complex referred to as the cap-binding complex or eIF4F. eIF4F consists of the cap-binding protein eIF4E, the scaffolding protein eIF4G, and the ATP-dependent RNA helicase eIF4A, which unwinds the secondary structure in the 5 0 -untranslated region (5 0 -UTR) of the mRNA. The eIF4F-bound mRNA recruits the 43S initiation complex. The 43S complex consists of the 40S ribosomal subunit, the ternary complex containing an initiator tRNA molecule (eIF2GTPMet-tRNAi Met ), and the multisubunit initiation factor eIF3. The 43S initiation complex scans the 5 0 -UTR for the initiation codon. Whenever the initiation AUG codon is recognized, the 40S subunit is joined by a 60S subunit to form an elongationcompetent 80S ribosome. The recognition of the AUG initiation codon and the delivery of the initiator met-tRNA involve a GTP hydrolysis step, which leaves the eIF2 complex in the inactive guanosine diphosphate (GDP)-bound state. The translation initiation factor eIF2B, regenerates an active ternary complex via its guanine nucleotide exchange activity (GEF) and by recruiting a new initiator met-tRNA to the complex. The recycling of the ternary complex is essential for continuing rounds of translation initiation [20] . During stress states, eIF2 phosphorylation at the a subunit (eIF2a) acts as an inhibitor of the eIF2B activity and stalls ternary complex recycling, leading to global inhibition of protein synthesis [21] .
In response to cellular stress, a diverse set of eIF2a kinases are activated that converge on the phosphorylation of eIF2a with translational repression and consequent decreased protein synthesis [22 && ]. The four identified eIF2a kinases include: eIF2a kinase 1/heme-regulated inhibitor (HRI) activated during heme deficiency; eIF2a kinase 2/protein kinase RNA-activated (PKR) activated by double stranded RNA introduced during viral infection; eIF2a kinase 3/PKR-like endoplasmic reticulum kinase (PERK) activated during endoplasmic reticulum stress; and eIF2a kinase 4/general control nonderepressed 2 (GCN2). The eIF2a kinases recognize and phosphorylate Ser 51 on eIF2a, a central step in the integrated stress response that inhibits global protein synthesis [22 && ]. Certain mRNA translation, however, is upregulated including those for the transcription factor ATF4 and CHOP that restore cellular protein homeostasis [23] . Despite extensive work on the biology of integrated stress responses, and eIF2a phosphorylation, the regulation of the cellular stress response to hyperammonemia in liver disease are being dissected only recently [16 && ].
MEDIATORS OF THE LIVER-MUSCLE AXIS
A number of metabolic, hormonal, and cytokine perturbations have been reported in cirrhosis that can result in dysregulated muscle proteostasis [1 && ]. Hyperammonemia, reduction in testosterone, reduced branched-chain amino acids, endotoxemia, and elevated circulating tumor necrosis factor a have all been suggested to contribute to muscle loss [24 & ,25]. The focus of this review will be on ammonia-mediated disturbed muscle proteostasis because hyperammonemia is a consistent abnormality in cirrhosis and therapies to lower ammonia are available for therapeutic application [8
Ammonia is a cytotoxic compound that is generated from amino acid catabolism, purine turnover and gut microbial metabolism. Physiologically, ammonia disposal occurs in the hepatocytes via ureagenesis. In cirrhosis, a combination of hepatocellular dysfunction and portosystemic shunting result in elevated circulating ammonia. Hepatic encephalopathy is the best studied clinical consequence of ammonia-induced organ toxicity with morbidity and mortality [26] . Past reports of increased ammonia uptake by the skeletal muscle based on noninvasive methods were followed by direct quantification that showed increased skeletal muscle ammonia concentrations in patients with liver disease. On account of its cytotoxicity, increased ammonia in the muscle is converted to glutamate and glutamine that is subsequently exported to the plasma. It was thought that the skeletal muscle functioned as a metabolic sink for ammonia with very limited studies on its adverse effects on muscle phenotype or proteostasis. Studies in the past decade have, however, shown that ammonia induces a series of molecular and metabolic perturbations in the skeletal muscle that result in dysregulated proteostasis and sarcopenia [8 & ,26] . As ammonia is a simple chemical (four elements, three hydrogen atoms and one nitrogen atom), it is likely to initiate homeostatic biochemical responses to neutralize its toxicity. There is, therefore, great interest in identifying what we call as 'interface molecules', which are signaling proteins that detect metabolic perturbations to initiate a series of molecular responses. The mechanisms by which these biochemical responses initiate molecular perturbations are currently being dissected using integrated molecular-metabolic approaches [1 && ].
AMMONIA TRANSCRIPTIONALLY UPREGULATES MYOSTATIN
The mechanisms by which ammonia uptake is increased in the muscle are currently being investi- 
HYPERAMMONEMIC STRESS RESPONSE
In addition to myostatin-mediated responses, hyperammonemia also induces a cellular stress response, which is mediated by an eIF2a kinase, general control nondepressed 2 (GCN2), which is known to be activated during amino acid deficiency [16 && ]. Cellular amino acid deficiency results in increased cytoplasmic uncharged tRNAs (not bound to their cognate amino acids) that in turn activate GCN2 and consequently its target, eIF2a with reduction in mRNA translation and protein synthesis [31] . In cellular systems of hyperammonemia, L-leucine supplementation reversed impaired protein synthesis, GCN2 activation, and eIF2a phosphorylation [16 && ]. These data complement human studies with L-leucine-enriched amino acid mixture reversing the molecular and metabolic perturbations in cirrhotic skeletal muscle [16 && ]. Interestingly, despite activation of GCN2 and reversal by L-leucine supplementation, cellular concentration of leucine was unchanged in response to hyperammonemia that was consistent with previous data on muscle amino acid concentrations in cirrhosis. These data suggest that L-leucine in the skeletal muscle is partitioned into the mitochondrial compartment for metabolic utilization or remains in the cytoplasmic compartment and then into the lysosomes for activation of mTORC1 signaling via the Rag proteins. Consistently, mitochondrial leucine entry was higher during hyperammonemia in myotubes suggesting that GCN2 activation was because of compartmental partitioning of L-leucine [16 && ]. The eIF2a kinases are stress-specific and as mentioned above, hyperammonemia activated the GCN2 kinase [16 && , 31, 32] . Some mRNAs that are preferentially translated during cellular stress to promote recovery and resume protein synthesis include GADD34, a component of the protein phosphatase 1 (PP1) and ATF4, the master regulator of the stress-induced transcriptome [23, 33, 34] . Interestingly, in the well studied amino acid deficiency response, an integrated stress response is initiated via the GCN2-eIF2a phosphorylation axis with preferential increased translation of the ATF4 and GADD34 mRNAs [22 && ]. During hyperammonemia, however, there is persistent GCN2 activation with absence of ATF4 and GADD34 translation with resultant persistent impaired protein synthesis and perturbed proteostasis [16 && ,35 && ]. Targeting these steps to restore muscle proteostasis is an attractive potential therapeutic strategy.
OTHER FACTORS THAT CONTRIBUTE TO DISTURBED ANABOLIC RESISTANCE AND DYSREGULATED SKELETAL MUSCLE PROTEOSTASIS IN CIRRHOSIS
Even though hyperammonemia-induced alterations in proteostasis, other metabolic, hormonal and cytokine perturbations in cirrhosis also result in impaired protein synthesis and increased autophagy [1
&&
]. These include a reduction in testosterone in men, endotoxemia, alterations in gut microbiome, which promotes ammoniagenesis, alterations in plasma amino acid concentrations, decreased mobility and the consequence of complications of cirrhosis including infections, gastrointestinal bleeding, encephalopathy with poor oral intake, and portal hypertensive enteropathy. These have been reviewed recently and the interested reader is referred to several recent publications in this area [1
TREATMENT OPTIONS BASED ON DYSREGULATED PROTEOSTASIS
Given the proteostasis perturbations during hyperammonemia, a number of treatment options have been evaluated (Table 1) . Stimulating protein synthesis using anabolic steroids, including testosterone, has been evaluated recently in male patients with cirrhosis, which showed improvement in muscle mass with a nonsignificant improvement in survival [24 & ]. Whether the molecular perturbations, however, are reversed is not known. Previous studies on amino acid and dietary supplementation have also not been consistently effective [6] . Ammonialowering therapies are currently approved for human use but have not been systematically evaluated for reversal of the molecular and metabolic perturbations and sarcopenia in human cirrhosis.
Recently, long-term ammonia lowering in cellular and a rat model of hyperammonemia was reported to reverse impaired protein synthesis, increased autophagy, and the molecular perturbations including increased myostatin, impaired mTORC1 signaling, and increased phosphorylation of GCN2-eIF2a [13 && ]. Whether these will benefit individuals need to be tested in prospective clinical trials. It must, however, be emphasized that even the most sophisticated methods to quantify muscle mass and function are relatively insensitive, and small changes may not be detected. Long-term, well designed human studies are necessary to determine if ammonia-lowering is an effective strategy to reverse perturbed proteostasis and translate into reversal of sarcopenia.
A single dose of a leucine-enriched amino acid mixture was also reported in a small group of patients with alcoholic cirrhosis, to reverse impaired mTORC1 signaling, phosphorylation of eIF2a, and to restore the molecular responses of dysregulated proteostasis [35 && ]. Protein synthesis in response to the amino acid mixture was similar to that in healthy controls. Whether these benefits, however, are maintained in response to long-term replacement is currently unknown.
In addition to nutrient and nutriceutical interventions, exercise is another approach to improve proteostasis [1 && , 36, 37] . Both resistance and endurance exercise have been reported to be beneficial in small, short-term clinical studies with limited readouts. It must be reiterated that ammonia results in contractile dysfunction and the exercising muscles generate ammonia both of which may adversely affect the beneficial response to exercise in cirrhosis [38 39] . Recently, barriers to nutritional supplements and physical activity have been reported, which can be targeted for improving proteostasis as exercise promotes protein homeostasis [40] . Rigorous data are needed to determine the molecular responses to exercise in cirrhosis and interventions to improve mitochondrial function, substrate utilization, and contractile responses may be necessary to complement physical activity alone.
Newer approaches including targeting myostatin [28] , providing cell-permeable TCA cycle intermediates, specifically a-ketoglutarate [17 & ], protecting against mitochondrial reactive oxygen species generation, and inhibiting eIF2a phosphorylation and signaling are exciting areas, which are needed to be determined in preclinical studies followed by clinical studies.
CONCLUSION
Despite a number of abnormalities in cirrhosis, hyperammonemia is observed consistently and contributes to both impaired protein synthesis and increased autophagy-dependent proteolysis. Signaling abnormalities that result in dysregulated proteostasis include myostatin-dependent impaired mTORC1 signaling and hyperammonemic stress response characterized by a GCN2-mediated eIF2a phosphorylation and translational repression with a modified cellular stress response. Additional contributors to disordered proteostasis include reduction in ATP synthesis and increased reactive oxygen species because of cataplerosis of aKG and impaired mitochondrial function. Long-term ammonialowering therapy and leucine-enriched amino acid mixture hold promise as therapeutic options (Fig. 1) .
Nardelli S, Lattanzi B, Torrisi S, et al. Sarcopenia is risk factor for development of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt placement. Clin Gastroenterol Hepatol 2017; 15:934-936. This group has published in the past that sarcopenia in cirrhosis increases the risk of encepahlopathy, another major consequence of hyperammonemia. This work is of high significance to hepatologists and those interested in the clinical consequences of sarcopenia in cirrhosis. Even though this is a review, this is recommended for anyone interested in the consequences of sarcopenia in patients on the liver-transplant waiting list. Sarcopenia adversely affects patient outcomes while on the waiting list increasing waitlist morbidity and mortality. This is an elegant review of skeletal muscle proteostasis that explains the process of protein homeostasis with a focus on protein synthesis and proteolysis. Additional components of proteostasis include folding, secretion, and storage and the entire process is a dynamic, energy-intense process involving multiple subcellular organelles. 13. This is the first preclinical study to evaluate skeletal muscle proteostasis responses including the molecular regulatory pathways during hyperammonemia and its partial reversal in response to 4 weeks of ammonia lowering using clinically available therapies. This work will be of interest to clinicians and scientists evaluating how ammonia regulates protein metabolism in the skeletal muscle. This work is a detailed characterization of how the skeletal muscle that is not capable of generating urea, metabolizes ammonia. Detailed functional studies using high sensitivity respirometry show how cataplerosis adversely affects muscle mitochondrial oxidation, ATP generation and evaluates an anaplerotic substrate to reverse these processes. Even though flux studies to determine the cataplerosis/ anaplerosis are not evaluated, the large number of studies lay the foundation for future potential interventions to reverse skeletal muscle bioenergetic dysfunction during hyperammonemia. As proteostasis is an energy-dependent process, reduced mitochondrial function and ATP content in the muscle in response to ammonia is likely to contribute to dysregulated proteostasis during hyperammonemia. 
